PDCD1 and myelodysplastic syndrome: To test this hypothesis, we developed an investigator-initiated phase 1 trial in transplant-ineligible patients with MDS/low blast count AML incorporating the anti–programmed cell death protein-1 (PD-1) ICI nivolumab.